Literature DB >> 15721727

Antagonism of profound cisatracurium and rocuronium block: the role of objective assessment of neuromuscular function.

Aaron F Kopman1, David J Kopman, Jennifer Ng, Lee M Zank.   

Abstract

STUDY
OBJECTIVE: The purpose of this study is to determine the incidence of significant (train-of-four [TOF] ratio <0.70), but clinically undetectable (TOF ratio >0.40), residual neuromuscular block after neostigmine antagonism of profound cisatracurium (CIS) or rocuronium (ROC) block.
DESIGN: Prospective, randomized, open-label study.
SETTING: University hospital. PATIENTS: Forty ASA physical status I and II undergoing elective surgical procedures.
INTERVENTIONS: Anesthesia was induced with propofol 1.5 to 2.5 mg/kg IV plus fentanyl 2 to 4 mug/kg and maintained with N(2)O/desflurane plus narcotic supplementation. The electromyographic response of the adductor pollicis was recorded. Train-of-four stimulation was given every 20 seconds. Twitch height (T1) and TOF fade ratio were continuously recorded. In group 1 (n = 20), neuromuscular block was induced with CIS 0.10 mg/kg, and T1 was maintained at 5% of control by a constant infusion of CIS until the end of surgery. One minute after the termination of the infusion, neostigmine 0.05 mg/kg was administered. T1 and TOF values were monitored continuously for the next 20 minutes. Group 2 (n = 20) is identical to group 1 except that the initial drug was ROC 0.60 mg/kg, and paralysis was maintained with an infusion of ROC.
MEASUREMENTS AND MAIN RESULTS: There were no significant differences in the recovery patterns of CIS vs ROC. The duration (bolus to end of infusion) in both groups averaged 2.7 hours, and the mean cumulative dose of relaxant approximated 4 x the ED(95). T1 at the time of reversal was 6% (4%-10%) of control. Mean TOF ratios at 10, 15, and 20 minutes were 0.55, 0.71, and 0.0.81, respectively. Return to a TOF ratio >0.40 was always achieved in 15 minutes or less. However, at 20 minutes postreversal, 5 of 40 subjects had TOF ratios <0.70 and only 11 individuals had recovered to a TOF ratio of 0.90 or greater.
CONCLUSIONS: Most clinicians cannot detect tactile fade once the TOF ratio exceeds 0.40. When reversing profound block, an objective monitor of neuromuscular function is required if the extent of residual block is to be assessed with any confidence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721727     DOI: 10.1016/j.jclinane.2004.03.009

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  6 in total

1.  Residual Paralysis: Does it Influence Outcome After Ambulatory Surgery?

Authors:  Hassan Farhan; Ingrid Moreno-Duarte; Duncan McLean; Matthias Eikermann
Journal:  Curr Anesthesiol Rep       Date:  2014-12

2.  Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing.

Authors:  M Eikermann; S Zaremba; A Malhotra; A S Jordan; C Rosow; N L Chamberlin
Journal:  Br J Anaesth       Date:  2008-06-16       Impact factor: 9.166

3.  A randomized-controlled trial of sugammadex versus neostigmine: impact on early postoperative strength.

Authors:  Ramon E Abola; Jamie Romeiser; Sabeen Rizwan; Brandon Lung; Ruchir Gupta; Elliott Bennett-Guerrero
Journal:  Can J Anaesth       Date:  2020-05-13       Impact factor: 5.063

4.  The use of sugammadex for bariatric surgery: analysis of recovery time from neuromuscular blockade and possible economic impact.

Authors:  Edoardo De Robertis; Geremia Zito Marinosci; Giovanni Marco Romano; Ornella Piazza; Michele Iannuzzi; Fabrizio Cirillo; Stefania De Simone; Giuseppe Servillo
Journal:  Clinicoecon Outcomes Res       Date:  2016-06-29

5.  Reversal agents: do we need to administer with neuromuscular monitoring - an observational study.

Authors:  Shilpa Goyal; Nikhil Kothari; Deepak Chaudhary; Shilpi Verma; Pooja Bihani; Mahaveer Singh Rodha
Journal:  Indian J Anaesth       Date:  2018-03

6.  Neuromuscular Blockade Agents Reversal with Sugammadex Compared to Neostigmine in the Living Kidney Donors.

Authors:  Thuy Luu Quang; Huyen Nguyen Thi Thu; Kinh Nguyen Quoc; Ha Nguyen Thu; Dong Pham Van; Nguyen Le Bao Tien; Vo Van Thanh; Vu Thi Nga; Chu Dinh Toi
Journal:  Open Access Maced J Med Sci       Date:  2019-12-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.